AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14595084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 14595084 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of OROS methylphenidate HCL (MPH)
Number of subjects: 47
Study 10898926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol at 6 or 12 or 18 mg/day for 3 weeks
Number of subjects: 52
Study 10898926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonapride at 18 mg/day for 3 weeks
Number of subjects: 52
Study 8967857 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaplasia and dysplasia of epithelial cells
Number of subjects: 0
Study 1595852 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study 1595852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6611585 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea (1.0 g/kg b.w.)
Number of subjects: 33
Study 6611585 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study 29136683 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Group Psychotherapy (MCGP)
Number of subjects: 218
Study 29136683 — intervention group
Group type: COMPARATOR
Intervention: Supportive group psychotherapy (Control)
Number of subjects: 218
Study 26362090 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with short-course androgen deprivation therapy (ADT) (4 months of GnRH agonist therapy and antiandrogen)
Number of subjects: 1979
Study 26362090 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 1979
Study 26362090 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course ADT
Number of subjects: 1979
Study 25376267 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 200
Study 25376267 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 200
Study 22643708 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified rice (Ultrarice(®)) 50g providing 56.4mg elemental Fe
Number of subjects: 216
Study 22643708 — intervention group
Group type: COMPARATOR
Intervention: Standard rice (control)
Number of subjects: 216
Study 20056344 — intervention group
Group type: COMPARATOR
Intervention: Standard thermoplastic masks (SM)
Number of subjects: 20
Study 20056344 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin‐sparing masks (SSM)
Number of subjects: 20
Study 18616797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise interventions
Number of subjects: 15
Study 11157353 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 0
Study 11157353 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii and Enterococcus faecium SF 68
Number of subjects: 0
Study 11157353 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 0
Study 11157353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milks containing Lactobacillus rhamnosus GG
Number of subjects: 0
Study 9196111 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized gentamicin (GM) 40 mg, twice per day for 3 days
Number of subjects: 28
Study 9196111 — intervention group
Group type: COMPARATOR
Intervention: 0.45% saline (saline), twice per day for 3 days
Number of subjects: 28
Study 8311085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (≤5 mg/kg/d)
Number of subjects: 14
Study 8311085 — intervention group
Group type: EXPERIMENTAL
Intervention: Second biopsy after further 18 months of therapy
Number of subjects: 14
Study 8311085 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cyclosporine therapy
Number of subjects: 14
Study 3582481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg o.d.)
Number of subjects: 0
Study 3582481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg o.d.)
Number of subjects: 0
Study 3582481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31981567 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory Stimulation by L-Menthol (OSM)
Number of subjects: 28
Study 31981567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Olfactory Stimulation by Strawberry-scented patch)
Number of subjects: 28
Study 31981567 — intervention group
Group type: COMPARATOR
Intervention: Sham condition (breathing through a face mask without OSP)
Number of subjects: 28
Study 31648099 — intervention group
Group type: EXPERIMENTAL
Intervention: Patritumab + cetuximab + platinum therapy
Number of subjects: 87
Study 31648099 — intervention group
Group type: COMPARATOR
Intervention: Placebo + cetuximab + platinum therapy
Number of subjects: 87
Study 28950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoengineered imgatuzumab (GA201; 700 mg)
Number of subjects: 44
Study 28950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoengineered imgatuzumab (GA201; 1400 mg)
Number of subjects: 44
Study 28950289 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (standard dosing)
Number of subjects: 44
Study 28950289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antibodies
Number of subjects: 44
Study 26358336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen blocker cream applied three times daily for 30 days
Number of subjects: 0
Study 26358336 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied three times daily for 30 days
Number of subjects: 0
Study 26358336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen blocker cream in adults
Number of subjects: 0
Study 26358336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen blocker cream in children
Number of subjects: 0
Study 22796122 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol/stanol softgel capsules (1.8 g/d)
Number of subjects: 28
Study 22796122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21185525 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing awareness meditation (BAM)
Number of subjects: 166
Study 21185525 — intervention group
Group type: EXPERIMENTAL
Intervention: Botvin LifeSkills Training (LST)
Number of subjects: 166
Study 21185525 — intervention group
Group type: COMPARATOR
Intervention: Health education control (HEC)
Number of subjects: 166
Study 18164469 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study 18164469 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 0
Study 15935540 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite restorations
Number of subjects: 60
Study 15935540 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite restorations
Number of subjects: 60
Study 15935540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic restorations
Number of subjects: 60
Study 15935540 — intervention group
Group type: COMPARATOR
Intervention: All groups (Direct, Indirect, Ceramic)
Number of subjects: 60
Study 14630439 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-firm mattress (H(s)=5.6)
Number of subjects: 313
Study 14630439 — intervention group
Group type: COMPARATOR
Intervention: Firm mattress (H(s)=2.3)
Number of subjects: 313
Study 10877012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 32
Study 10877012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 100 mg
Number of subjects: 32
Study 10877012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 250 mg
Number of subjects: 32
Study 10877012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 375 mg
Number of subjects: 32
Study 10877012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9126665 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-enanthate (200 mg/week intramuscularly)
Number of subjects: 14
Study 9126665 — intervention group
Group type: EXPERIMENTAL
Intervention: Testolactone (1 g/day orally)
Number of subjects: 14
Study 9126665 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-enanthate (200 mg/week) + Testolactone (1 g/day)
Number of subjects: 14
Study 8243792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day cyclobenzaprine at bedtime
Number of subjects: 40
Study 8243792 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day cyclobenzaprine in three equal doses daily
Number of subjects: 40
Study 28870463 — intervention group
Group type: EXPERIMENTAL
Intervention: rMal d 1
Number of subjects: 60
Study 28870463 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1
Number of subjects: 60
Study 28870463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26682629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dancing group
Number of subjects: 32
Study 26682629 — intervention group
Group type: COMPARATOR
Intervention: Health-related exercise group
Number of subjects: 32
Study 25615800 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model of care
Number of subjects: 327
Study 25615800 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 327
Study 23993401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days SBRT (48 Gy for tumors ≤ 3 cm, 52 Gy for tumors > 3 cm)
Number of subjects: 54
Study 23993401 — intervention group
Group type: COMPARATOR
Intervention: 11 days SBRT (48 Gy for tumors ≤ 3 cm, 52 Gy for tumors > 3 cm)
Number of subjects: 54
Study 23993401 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days SBRT
Number of subjects: 54
Study 23993401 — intervention group
Group type: COMPARATOR
Intervention: 11 days SBRT
Number of subjects: 54
Study 20678219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined primary health-care and community-based exercise intervention for 6 months
Number of subjects: 243
Study 20678219 — intervention group
Group type: COMPARATOR
Intervention: Individual written prescription for exercise (Control)
Number of subjects: 243
Study 18483084 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of primary tumor (Group A)
Number of subjects: 8
Study 18483084 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 8
Study 16488235 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) analysis of shoulder strength data
Number of subjects: 45
Study 16488235 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM-based score
Number of subjects: 45
Study 12594697 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking-radiation
Number of subjects: 476
Study 12594697 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (BA) alone
Number of subjects: 476
Study 11081987 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized extract SHR/5 of Rhodiola rosea (RRE)
Number of subjects: 56
Study 11081987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9225617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence trials with implicit instructions
Number of subjects: 0
Study 9225617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence trials with explicit instructions
Number of subjects: 0
Study 9225617 — intervention group
Group type: COMPARATOR
Intervention: All random trials
Number of subjects: 0
Study 9225617 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial reaction time task performance
Number of subjects: 0
Study 9225617 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex structural characteristics sequence
Number of subjects: 0
Study 9225617 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition memory measures
Number of subjects: 0
Study 8234437 — intervention group
Group type: EXPERIMENTAL
Intervention: Agiolax
Number of subjects: 77
Study 8234437 — intervention group
Group type: COMPARATOR
Intervention: lactulose
Number of subjects: 77
Study 2418400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (B‐CMF) chemotherapy prior to and two courses after standard therapy
Number of subjects: 83
Study 2418400 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (preoperative irradiation followed by radical surgery)
Number of subjects: 83
Study 31380764 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-enabling methods (MOVit)
Number of subjects: 24
Study 31380764 — intervention group
Group type: COMPARATOR
Intervention: Conventional joystick control
Number of subjects: 24
Study 29183782 — intervention group
Group type: EXPERIMENTAL
Intervention: dolutegravir/abacavir/lamivudine
Number of subjects: 833
Study 29183782 — intervention group
Group type: COMPARATOR
Intervention: efavirenz (EFV)/tenofovir (TDF)/emtricitabine (FTC)
Number of subjects: 833
Study 27310254 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg daily valganciclovir (group 1)
Number of subjects: 196
Study 27310254 — intervention group
Group type: COMPARATOR
Intervention: 900 mg daily valganciclovir (group 2)
Number of subjects: 196
Study 24297654 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential excisional hemorrhoidectomy (CEH)
Number of subjects: 688
Study 24297654 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy (FH)
Number of subjects: 688
Study 22594981 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical photodynamic therapy using methylene blue and Hypericum perforatum extract
Number of subjects: 0
Study 22594981 — intervention group
Group type: COMPARATOR
Intervention: Conventional approaches (not specified)
Number of subjects: 0
Study 20718337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous Mechanical Pressure (CMP) applied to the ipsilateral lateral and medial plantar surface at 50% of leg and foot weight.
Number of subjects: 16
Study 19005632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing-aid fitting according to two different procedures (optimizing speech intelligibility scores and strictly implemented fitting formula)
Number of subjects: 0
Study 19005632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing-aid fitting according to either procedure
Number of subjects: 0
Study 19005632 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with greater hearing loss
Number of subjects: 0
Study 19005632 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time hearing aid users
Number of subjects: 0
Study 19005632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hearing-aid fitting
Number of subjects: 0
Study 19005632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing-aid fitting
Number of subjects: 0
Study 15832335 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure condition (0.63 W/kg 1 g averaged SAR)
Number of subjects: 58
Study 15832335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low exposure condition (0.063 W/kg 1 g averaged SAR)
Number of subjects: 58
Study 15832335 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (at least 50 dB below low exposure)
Number of subjects: 58
Study 12887472 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 mg
Number of subjects: 284
Study 12887472 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg
Number of subjects: 284
Study 10475316 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60
Study 10475316 — intervention group
Group type: COMPARATOR
Intervention: 1:1 mixture of 2% plain lidocaine and 0.5% plain bupivacaine
Number of subjects: 60
Study 8941467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (HbA1c target of 4.0-6.1%)
Number of subjects: 153
Study 8941467 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (general medical care, one shot of insulin per day)
Number of subjects: 153
Study 1750748 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate eyedrops
Number of subjects: 900
Study 1750748 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline hydrochloride eyedrops
Number of subjects: 900
Study 7201905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2 IV) administered in the morning (6:00 A.M.)
Number of subjects: 11
Study 7201905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2 IV) administered in the evening (6:00 P.M.)
Number of subjects: 11
Study 30635477 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab induction followed by glatiramer acetate (GA) monotherapy
Number of subjects: 55
Study 30635477 — intervention group
Group type: COMPARATOR
Intervention: Placebo induction followed by glatiramer acetate (GA) monotherapy
Number of subjects: 55
Study 28835387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and leucine-enriched whey protein medical nutrition drink (21 g leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D3)
Number of subjects: 24
Study 28835387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and leucine-enriched whey protein medical nutrition drink
Number of subjects: 24
Study 28835387 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo
Number of subjects: 24
Study 26035650 — intervention group
Group type: EXPERIMENTAL
Intervention: North Carolina Eat Smart, Move More Community Grants program (2010-2011)
Number of subjects: 2138
Study 26035650 — intervention group
Group type: COMPARATOR
Intervention: North Carolina Eat Smart, Move More Community Grants program (2011-2012)
Number of subjects: 2138
Study 24755056 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle group (DB, n=55)
Number of subjects: 110
Study 24755056 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle group (SB, n=55)
Number of subjects: 110
Study 22674240 — intervention group
Group type: EXPERIMENTAL
Intervention: Online occupational postural and exercise intervention
Number of subjects: 100
Study 19507458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZO group)
Number of subjects: 62
Study 19507458 — intervention group
Group type: COMPARATOR
Intervention: Prescribed physical activity (PA group)
Number of subjects: 62
Study 17418019 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning (Precond group)
Number of subjects: 96
Study 17418019 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (Postcond group)
Number of subjects: 96
Study 17418019 — intervention group
Group type: COMPARATOR
Intervention: Reinfusion (IR group)
Number of subjects: 96
Study 16213935 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-coated tympanostomy tubes
Number of subjects: 170
Study 16213935 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tympanostomy tubes
Number of subjects: 170
Study 12456630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic oral estrogen/progestin (n = 25)
Number of subjects: 126
Study 12456630 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-cycle oral estrogen/quarterly progestin (n = 32)
Number of subjects: 126
Study 12456630 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral estrogen/progestin (n = 21)
Number of subjects: 126
Study 12456630 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral estrogen/intrauterine progestin (n = 22)
Number of subjects: 126
Study 12456630 — intervention group
Group type: COMPARATOR
Intervention: No HRT (n = 26)
Number of subjects: 126
Study 10426734 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise classes led by a physiotherapist including strengthening exercises, stretching exercises, relaxation session, and brief education on back care.
Number of subjects: 187
Study 10426734 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise classes led by a physiotherapist
Number of subjects: 187
Study 10426734 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care management (Control)
Number of subjects: 187
Study 8837970 — intervention group
Group type: EXPERIMENTAL
Intervention: Full recovery of delusional beliefs
Number of subjects: 50
Study 8837970 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial recovery of delusional beliefs
Number of subjects: 50
Study 8837970 — intervention group
Group type: EXPERIMENTAL
Intervention: High insight
Number of subjects: 50
Study 8837970 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of insight during recovery
Number of subjects: 50
Study 8837970 — intervention group
Group type: EXPERIMENTAL
Intervention: Average degree of insight
Number of subjects: 50
Study 8837970 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight and positive psychotic symptoms
Number of subjects: 50
Study 1973085 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.075 mg once daily)
Number of subjects: 22
Study 1973085 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.075-0.15 mg)
Number of subjects: 22
Study 1973085 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (5 mg divided daily)
Number of subjects: 22
Study 1973085 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (5-10 mg)
Number of subjects: 22
Study 1973085 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 22
Study 7213506 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily dosage (0.25 mg)
Number of subjects: 48
Study 7213506 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily dosage (0.125 mg)
Number of subjects: 48
Study 7213506 — intervention group
Group type: EXPERIMENTAL
Intervention: Four times daily dosage (0.0625 mg)
Number of subjects: 48
Study 7213506 — intervention group
Group type: COMPARATOR
Intervention: All dosage frequencies
Number of subjects: 48
Study 31182128 — intervention group
Group type: EXPERIMENTAL
Intervention: Med-Stress intervention (sequential enhancement of self-efficacy and perceived social support)
Number of subjects: 1200
Study 31182128 — intervention group
Group type: EXPERIMENTAL
Intervention: Med-Stress intervention (sequential enhancement of perceived social support and self-efficacy)
Number of subjects: 1200
Study 31182128 — intervention group
Group type: COMPARATOR
Intervention: Active control strengthening self-efficacy
Number of subjects: 1200
Study 31182128 — intervention group
Group type: COMPARATOR
Intervention: Active control strengthening perceived social support
Number of subjects: 1200
Study 31182128 — intervention group
Group type: EXPERIMENTAL
Intervention: Med-Stress intervention
Number of subjects: 1200
Study 28923872 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 231
Study 25841539 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt (containing Streptococcus thermophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subspecies lactis (BB‐12) at 5 × 10(9) cfu/100 mL and 1 g of inulin)
Number of subjects: 149
Study 25841539 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yogurt
Number of subjects: 149